Eric Reynolds
Founder
Denteric
Denteric is developing precision immunotherapies targeting chronic infections caused by _Porphyromonas gingivalis_ (Pg), with an initial focus on severe periodontal disease. Their first product neutralizes circulating virulence factors produced by Pg, addressing the health complications associated with these infections.
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Chronic infections caused by _Porphyromonas gingivalis_ (Pg) can lead to severe periodontal disease and other health complications. Current treatments do not effectively neutralize the virulence factors (toxins) produced by _Pg_ that circulate in the blood.
Solution
Denteric is developing precision immunotherapies specifically targeting chronic _Porphyromonas gingivalis_ (Pg) infections. Their lead product is designed to neutralize circulating virulence factors produced by _Pg_, addressing the underlying cause of associated health complications, with an initial focus on severe periodontal disease. This approach aims to provide a more targeted and effective treatment option compared to existing methods.
Target Audience
The primary target audience includes patients suffering from severe periodontal disease and clinicians treating _Porphyromonas gingivalis_ (_Pg_) related diseases.
Features
- Immunotherapy targeting _Porphyromonas gingivalis_ (_Pg_)
- Neutralizes circulating virulence factors (toxins) produced by _Pg_
- Focus on treating severe periodontal disease